Company Encyclopedia
View More
name
Fate Therap
FATE.US
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd.
1.946 T
FATE.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking269/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-52.35%E
    • Profit Margin-2187.11%E
    • Gross Margin-1384.09%E
  • Growth ScoreE
    • Revenue YoY-46.92%E
    • Net Profit YoY12.42%C
    • Total Assets YoY-30.57%E
    • Net Assets YoY-35.40%E
  • Cash ScoreD
    • Cash Flow Margin-4.57%D
    • OCF YoY-46.92%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreB
    • Gearing Ratio31.89%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fate Therapeutics to Present at Piper Sandler Annual Healthcare Conference

    Fate Therapeutics Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York. The company will participate in a fireside chat at 9:00 AM ET and a cell therapy panel at 12:00 PM ET. Live webcasts will be available on the company's website.

    Reuters·
    US
    FATE
    +1.85%
    Reuters·
    US
    FATE
    +1.85%

    Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts

    Fate Therapeutics Inc. reported a Q3 net loss of $32.25 million, down from $47.68 million last year, amid restructuring efforts to streamline operations and extend its cash runway. Collaboration revenue fell to $1.74 million from $3.07 million. Despite losses, the company invested $25.84 million in R&D and focuses on strategic partnerships, notably with Ono Pharmaceutical, to advance its iPSC platform and clinical programs.

    Tip Ranks·
    US
    FATE
    +1.85%
    Tip Ranks·
    US
    FATE
    +1.85%

    Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities

    Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating for Fate Therapeutics with a $2.00 price target. The stock closed at $0.96. Ahmad, a 3-star analyst, has a 1.8% average return and a 54.71% success rate. Fate Therapeutics also received a Hold from Needham's Gil Blum, while H.C. Wainwright upgraded it to Buy on October 31.

    Tip Ranks·
    US
    FATE
    +1.85%
    Tip Ranks·
    US
    FATE
    +1.85%

    Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment

    TD Cowen analyst Tara Bancroft maintains a Hold rating on Fate Therapeutics due to the potential of FT819 in autoimmune treatment, with trials expected in 2026. Despite strategic growth in UK and EU markets, the need for further validation of Phase I trial data suggests caution. Bancroft, a 4-star analyst, emphasizes the stock's future growth potential amid current uncertainties.

    Tip Ranks·
    US
    FATE
    +1.85%
    Tip Ranks·
    US
    FATE
    +1.85%

    Fate Therap | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 1.741 M

    LB filings·
    US
    FATE
    +1.85%
    LB filings·
    US
    FATE
    +1.85%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer